A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan
Phase of Trial: Phase III
Latest Information Update: 09 Dec 2015
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Olmesartan medoxomil
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 14 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Apr 2014 Planned End Date changed from 1 Jun 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 07 Sep 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2013-001783-36).